News
Public · Published
Hims & Hers Health (NYSE:HIMS) posts Q3 2026 sales in line with estimates but full-year sales guidance misses expectations
Hims & Hers Health reported Q3 2026 revenue of $890.4 million, up 48.6% year over year and broadly in line with analysts' estimates. Its $885 million Q4 revenue guidance was below estimates, while the company also reported a $0.14 per-share GAAP loss and lower customer numbers than the previous quarter.
Published:
Updated:
What happened
Hims & Hers Health reported Q3 2026 revenue of $890.4 million, up 48.6% year over year and broadly in line with analysts’ estimates. Its $885 million Q4 revenue guidance was below estimates, while the company also reported a $0.14 per-share GAAP loss and lower customer numbers than the previous quarter.
Confirmed
Global impact / market context
Strong quarterly sales growth did not carry through to the outlook: Q4 revenue guidance is below analysts’ expectations. Lower customer numbers, weaker operating and free cash flow margins, and a GAAP loss may constrain the company’s ability to turn growth into durable profits and cash.
Analyst inference
The figures present a split picture for investors: revenue rose sharply and met estimates, but next-quarter guidance missed, and adjusted EBITDA, or earnings before interest, taxes, depreciation and amortization, was also below estimates. That combination may shift attention from growth alone toward customer retention and cost control.
Analyst inference
What to watch
- Compare Q4 revenue with the $885 million midpoint guidance and assess whether sales growth is slowing relative to the 48.6% reported for Q3. Confirmed
- Track customer counts in the next report; a continued decline could weaken repeat sales and make it harder to convert telehealth demand into revenue. Analyst inference
- Watch operating and free cash flow margins, which show how much sales remain after costs and how much cash the business generates. Analyst inference